Phosphatidylinositol 4-Phosphate Synthesis in Immunoisolated Caveolae-like Vesicles and Low Buoyant Density Non-caveolar Membranes*

Mark G. WaughDagger §, Durward Lawson, Siow Khoon TanDagger , and J. Justin HsuanDagger parallel **

From the Dagger  Ludwig Institute for Cancer Research, University College London Medical School, Courtauld Building, 91 Riding House Street, London W1P 8BT, the parallel  Department of Biochemistry and Molecular Biology, University College London, Gower Street, London WC1E 6BT, and the  Department of Molecular Pathology, Windeyer Institute for Medical Science, University College London, 46 Cleveland Street, London W1P 6DB, United Kingdom

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

This study examined phosphatidylinositol 4-phosphate (PtdIns4P) synthesis in caveolae that have been suggested to be discrete signaling microdomains of the plasma membrane and are enriched in the marker protein caveolin.

Caveolin-rich light membranes (CLMs) were isolated from A431 cells by detergent-free, discontinuous density-gradient centrifugation method. The CLM fraction was separated from the bulk of the cellular protein and was greatly enriched in PtdIns, PtdIns4P, and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and an adenosine-sensitive type II PtdIns 4-kinase activity. Preparation of CLMs by an OptiPrep-based cell fractionation procedure confirmed the co-localization of PtdIns 4-kinase and caveolin. Electron microscopy confirmed that an anti-caveolin antiserum immunopurified vesicles from CLMs that were within the size range described for caveolae in other systems. Co-immunoprecipitated PtdIns 4-kinase activity could utilize endogenous PtdIns, present within the caveolae-like vesicles, to produce PtdIns4P. The addition of recombinant phosphatidylinositol transfer protein increased PtdIns 4-kinase activity both in immunoisolated caveolae and CLMs. However, less than 1% of the total cellular PtdIns and PtdIns 4-kinase activity was present in caveolae-like vesicles, indicating that non-caveolar light membrane rafts are the main site for cellular PtdIns4P production.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

A vast number of extracellular stimuli are transduced via plasma membrane-associated tyrosine kinase and G protein-coupled receptors to activate the phosphoinositidase C (PIC)1 signaling pathway. Activation of PIC leads to hydrolysis of PtdIns(4,5)P2 to generate inositol(1,4,5)P3 and diacylglycerol, which lead in turn to increases in intracellular Ca2+ and the activation of protein kinase C, respectively (reviewed in Refs. 1 and 2). In recent years other cellular roles for PtdIns(4,5)P2 have been identified. For example, PtdIns(4,5)P2 possesses biological activity in its own right in controlling the organization of the actin cytoskeleton (3-5) and binding a subset of pleckstrin homology domain-containing proteins (6). Furthermore PtdIns(4,5)P2 and its immediate metabolic precursor PtdIns4P are substrates for phosphorylation at the 3' position by a family of enzymes known as the phosphoinositide 3-kinases (7). 3'-Phosphorylated polyphosphoinositides are thought to represent a novel class of signaling molecules that may regulate a range of intracellular target proteins, including, for example, the protein kinases Btk (8), PDK1 (9), and Akt (10). It is clear therefore, that levels of PtdIns4P and PtdIns(4,5)P2 may control multiple intracellular signal transduction cascades.

In A431 cells, occupation of epidermal growth factor (EGF) receptors leads to activation of phosphoinositide hydrolysis by PICgamma (11) and stimulation of a type II PtdIns 4-kinase (12). In addition, stimulated EGF receptors co-purify (13) and co-immunoprecipitate (14) with PtdIns 4-kinase activity, and there is evidence to suggest that PtdIns 4-kinase (15) may bind to a basic juxtamembrane region of the EGF receptor. Work from this laboratory has also established that the phosphoinositide transfer protein (PITP) can be co-immunoprecipitated with both EGF receptors and PtdIns 4-kinase activity in EGF-treated A431 cells (14). This evidence, coupled with the observation that PITP is required to reconstitute PICbeta (16) and PICgamma (17) signaling in cytosol-depleted cells, has led to the hypothesis that the receptor, phosphoinositide kinases, and PITP form a functional signaling complex in mitogen-activated cells (17).

Recent evidence has indicated that PtdIns4P, PtdIns(4,5)P2, and agonist-stimulated phosphoinositide hydrolysis may be highly compartmentalized in discrete Triton X-100-insoluble micro-domains of the plasma membrane that are enriched in caveolin, a recognized marker protein for caveolae (18). Caveolae, also known as plasmalemmal vesicles, are generally described as small flask shaped invaginations of the plasma membrane that are characteristically enriched in the integral membrane protein caveolin (19). They also contain cholesterol, sphingolipids (20, 21), and possibly an array of proteins involved in signal transduction (21-27). However, in a previous study PtdIns 4-kinase activity was found not to be localized to caveolae (28) suggesting that PtdIns4P was made elsewhere within the cell and somehow sequestered by caveolae. In addition, recent studies have called in to question the equivalence of Triton-insoluble membranes and caveolae. There is evidence to suggest that both receptors and G proteins may in fact localize to non-caveolar plasma membrane regions that do not contain caveolin but have a similar isopynic density to caveolae following equilibrium density gradient centrifugation (29, 30). These non-caveolar, low buoyant density membrane domains have been called detergent-insoluble, glycolipid-rich domains (DIGs) or membrane rafts, and it is possible that some of the functional properties previously assigned to caveolae may actually derive from molecules present in rafts as opposed to bona fide caveolae.

Given this background, we sought to further investigate the compartmentation of cellular PtdIns4P synthesis by examining whether caveolae represent major sites for the generation of PtdIns4P. Indeed, despite its central role in the regulation of cellular polyphosphoinositide levels, and the observation that only a proportion of the total cellular PtdIns may be available to replenish PtdIns4P during PIC activation, little is known about the organization of PtdIns4P synthesis at the plasma membrane or how the reported cellular compartmentation of phosphoinositide turnover may relate to agonist- and PITP-dependent PtdIns4P production (16, 17, 31).

The current study utilizes subcellular fractionation to isolate caveolin-enriched light membranes (CLMs) from A431 cells. We demonstrate that PtdIns4P synthesis is indeed concentrated within CLMs and that following immunopurification only a small proportion of the CLM PtdIns 4-kinase activity is associated with caveolae. In addition, using both CLMs and purified caveolae, we show first that endogenous PtdIns in these membrane subdomains is a substrate for a co-localized PtdIns 4-kinase and second that this activity is enhanced by the addition of PITP.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- [3H]Inositol with PT6-271 stabilizer (17.1Ci/mmol), [gamma -32P]ATP (4500-6000 Ci/mmol), and the ECL Western blotting detection system were purchased from Amersham Pharmacia Biotech. Monoclonal anti-caveolin IgG (mAb C060) and anti-caveolin polyclonal antiserum were obtained from Transduction Laboratories. Cell culture reagents were from Life Technologies, Inc. Prestained molecular weight markers and protein assay reagents were purchased from Bio-Rad. Protease inhibitor mixture tablets (COMPLETE) were from Boehringer Mannheim. ENHANCETM spray was purchased from DuPont. OsO4 and glutaraldehyde were purchased from Fluka. All other reagents were obtained from Sigma. PITPalpha was expressed as a His6-tagged construct in Sf9 cells and purified on nickel-nitrilotriacetic acid beads (Qiagen). The PITP thus obtained was further purified by gel filtration and shown to possess PtdIns transfer activity.2

Cell Culture-- A431 cells were maintained at 37 °C in a humidified incubator at 5% CO2. Cells were cultured in Dulbecco's modified Eagle's medium-glutamax medium containing 10% fetal calf serum, 50 IU/ml penicillin and 50 µg/ml streptomycin.

Isolation of CLM Domains-- CLM were obtained using a detergent-free method as described previously (32). All procedures were carried out at 4 °C. A431 cell monolayers grown to 50-70% confluence in 150-mm dishes were washed twice with phosphate-buffered saline and scraped into 2 ml of 100 mM Na2CO3, pH 11.0, containing protease inhibitors. Cells were disrupted by Dounce homogenization (15 strokes) followed by sonication (3 × 20-s bursts). 1 ml of homogenate was mixed with 1 ml of 90% sucrose in MBS buffer (25 mM Mes, 150 mM NaCl, pH 6.5) and placed in a 12-ml ultracentrifuge tube. A 5-35% discontinuous sucrose gradient was formed above the sample by layering on 6 ml of 35% sucrose solution followed by 4 ml of 5% sucrose solution. Both the 5 and 35% sucrose solutions were made in MBS buffer containing 250 mM Na2CO3. The sample was then centrifuged at 39,000 rpm for 16-18 h in a Beckman SW41 rotor. A light-scattering band was identified at the 5-35% sucrose interface that was enriched in caveolin but excluded the bulk of the cellular protein. 1-ml fractions were collected from the top of each gradient. The protein content of each fraction was determined using a Bradford assay (Bio-Rad).

Alternatively, CLM were isolated from A431 cells solely on the basis of their unique buoyant density using a carbonate-free fractionation protocol (23) that involved ultracentrifugation of sonicated plasma membranes in OptiPrep gradients.

Assays for Marker Proteins-- 5'-Nucleotidase was assayed using a commercial kit (Sigma), and NADPH-cytochrome c reductase activity was assayed using the method of Williams and Kamin (33).

Immunoblotting-- Samples were mixed with an equal volume of 2 × sample buffer and their protein content separated by SDS-polyacrylamide gel electrophoresis. Proteins were transferred to polyvinylidene difluoride and probed with various antibodies. Bound antibody was detected using the ECL system (Amersham Pharmacia Biotech).

Where appropriate, immunoblots were quantitated by two-dimensional densitometric analysis. The concentration of caveolin in the original cell homogenate was determined from immunoblots by constructing a standard curve of percent volume (a measure of signal intensity) against protein concentration for serial dilutions of the cell lysate. This relationship was found to be essentially linear for protein concentrations less than 0.6 mg/ml (data not shown). Therefore, the -fold purification of caveolin in the gradient fractions was calculated by dividing the percent volume by the amount of protein in the fraction.

Immunoprecipitation Studies-- For the isolation of caveolae under detergent-free conditions, CLM samples isolated by the carbonate method were precleared with dynal 280 beads coated with sheep anti-rabbit IgG. The cleared sample was incubated with anti-caveolin polyclonal antiserum for 1 h at 4 °C, followed by the addition of Dynabeads for 30 min at 4 °C. Immune complexes were collected by magnetic separation and washed four times in 20 mM Tris-HCl, pH 7.4.

Analysis of [3H]Inositol-labeled Phosphoinositides-- A431 cells were cultured in inositol-free medium containing 1% fetal calf serum in the presence of 2 µCi/ml [3H]inositol for 48 h. Cell monolayers were then washed twice in ice-cold phosphate-buffered saline and the CLM fraction was isolated. All steps were carried out on ice, and the Na2CO3 buffer used in these experiments contained EGTA (10 mM) to inhibit PIC activity, and it was found that more than 90% of the [3H]inositol-labeled phosphoinositides in the cell lysate were recovered in the fractions following density gradient centrifugation. Samples from gradient fractions and immunoprecipitates on Dynabeads were extracted with chloroform:methanol:1 M HCl (60:36:4). Samples were vortexed and centrifuged for 10 s in a microcentrifuge at 10,000 rpm. Organic phases were collected and re-extracted twice with methanol:1 M HCl (1:1). Samples were vortexed and centrifuged as before and the organic phase from each tube collected. Lipids were resolved by TLC on Silica-60 plates (Merck) which had been pretreated with 1% potassium oxalate, 2 mM EDTA in 50% methanol and developed using an acid solvent system composed of propan-1-ol:2 M acetic acid (65:35) containing 1% 5 M H3PO4. TLC plates were then sprayed with ENHANCETM to allow the visualization of phospholipids. Following fluorography the identity of radiolabeled lipid spots was determined by comparison with non-radiolabeled lipid standards visualized by iodine staining. The amount of radioactivity associated with each spot was determined by scraping spots off the TLC plates and liquid scintillation counting.

Phosphoinositide Kinase Assays-- For assays of PtdIns 4-kinase activity, each sample was mixed with an equal volume of assay buffer composed of 200 mM Tris-HCl, 40 mM MgCl2, 1 mM EGTA, 0.6% Triton X-100, 200 µM ATP, 0.1 mg/ml PtdIns, and 100 µCi/ml [gamma -32P]ATP. Samples were incubated at 37 °C for 30 min. Reactions were stopped and the samples extracted and separated by TLC as described for the analysis of [3H]inositol-labeled phosphoinositides. The amount of radioactivity associated with each spot identified by TLC was determined by counting Cerenkov radiation.

A similar protocol was employed for assaying endogenous PtdIns kinase activity, with the exception that the assay buffer did not include exogenous PtdIns or detergent.

Note that the density gradient buffers employed in this study were found not to interfere with PtdIns 4-kinase activity.

Electron Microscopy-- Electron microscopic analysis of CLM fractions and intact immunoprecipitated caveolae was performed essentially as described by Stan et al. (30). CLMs were fixed in suspension with 1% OsO4 and pelleted by centrifugation at 13,000 × g for 30 min in a microcentrifuge. The pellet was then stained with 2% uranyl acetate. The caveolae immunoisolated on magnetic Dynabeads were resuspended in 100 mM cacodylate buffer, pH 7.4, and fixed with 3% freshly prepared formaldehyde and 1.5% glutaraldehyde. The samples were treated with 1% OsO4, followed by staining in 2% uranyl acetate prior to subsequent processing for electron microscopy using a Jeol 1010 electron microscope operating at 80 kV as described previously (34).

Miscellaneous-- Dose-response data were analyzed using a standard four parameter logistic equation and computer-assisted curve fitting. Data are presented as the mean ± S.D.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Isolation of CLM Domains-- CLM domains were isolated according to the detergent-free method of Song et al. (32). This method has been used previously to demonstrate the interaction of p21ras with caveolin (32) and to confirm the localization of the novel protein flotillin within caveolae (35). In addition, this method avoids the use of Triton X-100, which has been shown to extract acylated proteins (32, 36) and phospholipids (21) from CLM. Caveolin, a 21-kDa integral membrane marker for caveolae, was reproducibly enriched in fraction 5 following density gradient centrifugation of A431 cell homogenates solubilized in sodium carbonate buffer (Fig. 1A). The CLM fraction was visible as a light-scattering band at the interface of the 5 and 35% sucrose layers and contained within fraction 5. In common with the findings of other groups, this fraction was separated from the bulk of the cellular protein content, which remained in the 45% sucrose layer at the bottom of the ultracentrifuge tube. The CLM fraction was depleted in 5'-nucleotidase activity, a marker for the plasma membrane and NADPH-cytochrome c reductase activity, which is a marker for the endoplasmic reticulum (Fig. 1B). These data are consistent with previous reports demonstrating that CLMs prepared in this way contain a small fraction of the total cellular protein and are separate from other cellular membranes (32, 37).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 1.   Isolation of CLMs. A, A431 cells were homogenized in the presence of 0.1 M sodium carbonate, pH 11.0, and the homogenate centrifuged in a 5-35% discontinuous sucrose density gradient. Fractions were collected and their protein content analyzed by 12% SDS-polyacrylamide gel electrophoresis. Proteins were electroblotted and probed with anti-caveolin antibody C060. The amount of caveolin immunoreactivity associated with each fraction was determined by densitometric analysis. B, distribution of protein (black-square), 5'-nucleotidase (bullet ), and NADPH-cytochrome c reductase (triangle ) activities in the density gradient fractions.

Analysis of [3H]Phosphoinositide Distribution-- The distribution of inositol phospholipids was assessed by density gradient centrifugation of an equilibrium [3H]inositol-labeled cell extract followed by TLC to identify the radiolabeled lipids in each gradient fraction. It was found that levels of [3H]PtdIns4P and [3H]PtdIns(4,5)P2 were greatest in fractions 4-6, which corresponded to the CLM fraction (Fig. 2). This region of the gradient contained 68.3 ± 14.6% (n = 3) of the total radiolabeled PtdIns, 61.9 ± 14% (n = 3) of the PtdIns4P, and 61 ± 11.3% (n = 3) of the cellular PtdIns(4,5)P2 pool. These data are in concordance with recent studies (18, 28), demonstrating that PtdIns, PtdIns4P, and PtdIns(4,5)P2 are present in CLM fractions, but the proportion of each phosphoinositide within CLM is reproducibly greater using the detergent-free conditions employed in this study. Liu et al. (21) also found that Triton X-100 was able to reduce the amount of PtdIns in CLM purified using detergent-free buffers. These results imply that phosphoinositides are highly compartmentalized within CLM domains. Furthermore, these data indicate that a mechanism exists whereby polyphosphoinositides are (a) synthesized elsewhere in the cell and then transported to CLM domains or (b) the enzymes responsible for inositol phospholipid synthesis are concentrated within CLM domains. The latter possibility was investigated by examining the distribution of PtdIns 4-kinase activity in the density gradient.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   [3H]Inositol-labeled phospholipids are present in CLM fractions. A431 cells were radiolabeled with [3H]inositol for 48 h prior to homogenization in the presence of 100 mM sodium carbonate and subcellular fractionation by centrifugation in a 5-35% discontinuous sucrose gradient. Fractions were collected from the gradient and lipids extracted using chloroform:methanol:HCl. PtdIns (black-square), PtdIns4P (open circle ), and PtdIns(4,5)P2 (open circle ) were separated by TLC and phosphoinositides visualized by spraying the TLC plate with ENHANCETM followed by fluorography. The amount of radioactivity associated with each spot was determined by scraping each spot and liquid scintillation counting. Data are representative of a single experiment repeated three times.

PtdIns 4-Kinase Distribution-- PtdIns 4-kinase activity was found to be highly concentrated within CLM-containing fractions (Fig. 3A). It was found that 60.1 ± 6.2% (n = 3) of the total PtdIns 4-kinase activity was present at the 5-35% sucrose interface. Note that these assays were carried out in the presence of a concentration of Triton X-100 that inhibits PtdIns 3-kinase activity.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Distribution of PtdIns 4-kinase activity. A, A431 cells were harvested in the presence of sodium carbonate, pH 11.0, homogenized, and fractionated by centrifugation in a 5-35% sucrose density gradient. PtdIns 4-kinase (bullet ) assays were carried out on samples from each gradient fraction as detailed under "Experimental Procedures." B, anti-caveolin blot on A431 fractions from low buoyant density caveolin-enriched membranes prepared on OptiPrep gradients. C, TLC of PtdIns 4-kinase assay against exogenous PtdIns carried out on the gradient fractions in B.

The co-localization of caveolin and PtdIns 4-kinase activity in a light density fraction was confirmed using a non-carbonate, detergent-free method for preparing CLMs (23). Using this technique, caveolin (Fig. 3B) and PtdIns 4-kinase (Fig. 3C) had very similar distributions.

Characterization of PtdIns Kinase Activity in the CLM Fraction-- Adenosine sensitivity has been established as a criterion that can differentiate between type II and type III PtdIns 4-kinase activities (38). Type II PtdIns 4-kinase activity is characteristically sensitive to adenosine inhibition in the micromolar range, whereas type III PtdIns 4-kinase activity is relatively insensitive to adenosine inhibition. It was found that the PtdIns 4-kinase activity associated with the CLM fraction was inhibited by adenosine with a Ki of 107 µM (n = 3) and a Hill slope of 1 (data not shown). This result suggested that the PtdIns 4-kinase activity under investigation was a type II isozyme. These data are in concordance with other studies that have shown that the membrane-associated PtdIns 4-kinase activity in A431 cells is predominately a type II activity (39). Addition of EGF (100 nM) for 2 min to the CLM fraction did not induce any significant increase in PtdIns4P synthesis. However, addition of recombinant PITPalpha (1 nM) resulted in a 40-60% increase in PtdIns 4-kinase activity in the CLM fraction (data not shown).

Immunopurification of Caveolae from the CLM Fraction-- To immunoisolate caveolae under detergent-free conditions we used a method based on that described by Stan et al. (30), with the exception that our initial CLM preparation was produced using the sodium carbonate-based fractionation method. This method utilizes antibody-coated magnetic beads to isolate caveolae from CLM preparations. Under these conditions, caveolin was immunoprecipitated from CLMs (Fig. 4A), whereas no caveolin was immunoprecipitated by the magnetic Dynabeads alone, indicating the specificity of the immunoprecipitation reaction (Fig. 4A). Furthermore, immunoblotting with an anti-caveolin monoclonal antibody carried out on control and immunoprecipitated samples indicated that 70-100% of the caveolin was cleared from the CLM fraction using the polyclonal anti-caveolin antiserum. The antiserum used in these experiments recognized the intracellular amino terminus of caveolin, indicating that the vast majority of the vesicles (produced by sonication) in the CLM fraction were in an intracellular side-out orientation.


View larger version (159K):
[in this window]
[in a new window]
 
Fig. 4.   Electron microscopy studies on CLMs and immunoisolated caveolae-like vesicles. Samples from CLM and anti-caveolin immunoprecipitates were analyzed by electron microscopy. A, electron micrograph (× 54,000, bar = 200 nm) of CLM fraction. Note the range of vesicle sizes, which can be classified into three main groups: large electron lucent vesicles of mean diameter 164.6 ± 72.8 nm (range, 110-416.5 nm), electron-dense vesicles of mean diameter 66.9 ± 24.6 nm (26-170.8 nm), and small electron lucent vesicles of mean diameter 72.8 ± 18.6 nm (range, 32-107 nm). Data were calculated from five separate fields. B, the majority of vesicles isolated by the anti-caveolin antiserum range in size from 50-75 nm. C, occasionally, larger vesicles of 100 nm are observed. D, infolding of larger vesicles is sometimes present, leading to the "vesicle whorl" shape. Note that the magnification in B-D is × 115,00 (bar = 100 nm).

Electron microscopy was employed to further characterize both the putative caveolae immunoisolated on Dynabeads and the CLM fraction. The CLM fraction was found to be composed of a heterogeneous mix of vesicles (Fig. 4A) composed of large size vesicles > 100 nm in diameter (22% of vesicles in CLM), interspersed with smaller electron lucent vesicles 50-100 nm of vesicles in diameter (33% of CLM vesicles) and a population of more electron-dense 50-100 nm vesicles (45% of CLM vesicles) wide. In contrast, the vesicle population isolated by immunoprecipitation with an anti-caveolin antiserum on Dynabeads was much more homogeneous in size (Fig. 4, B and C). The vesicles isolated by the anti-caveolin antiserum were electron lucent and 50-100 nm in diameter, which is similar to the size range of caveolae identified in situ (19, 40, 41). These results show that the vesicles isolated by an anti-caveolin antiserum resemble caveolae in size and buoyant density.

Caveolar PtdIns4P Synthesis-- When caveolae were immunoprecipitated from [3H]inositol-labeled CLMs, [3H]PtdIns was found to co-immunoprecipitate (Fig. 5, A and B). The amount of [3H]PtdIns that was specifically co-immunoprecipitated was not large enough to be reliably quantitated (<1% of the total cellular PtdIns), thus demonstrating that only a small proportion of the CLM-associated PtdIns was actually located in caveolae. Neither [3H]PtdIns4P nor [3H]PtdIns(4,5)P2 were detectable in the caveolin immunoprecipitate, indicating that the bulk of the cellular PtdIns4P and PtdIns(4,5)P2 are located in low buoyant density membranes that are distinct from caveolae.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 5.   Caveolin, [3H]PtdIns, and PtdIns 4-kinase activity co-immunoprecipitate. CLMs from A431 cells were prepared by carbonate extraction and buoyant density gradient centrifugation and subjected to immunoprecipitation with an anti-caveolin anti-serum. A, immunoblot showing that caveolin is immunoprecipitated from a CLM sample by an anti-caveolin antiserum (+anti-caveolin lanes). No caveolin associates with the Dynabeads alone (-anti-caveolin lanes). B, lipids were extracted from anti-caveolin and control immunoprecipitates prepared from [3H]inositol-labeled A431 cells. The TLC shown here demonstrates [3H]PtdIns is co-immunoprecipitated with caveolin but not with Dynabeads alone. C, assay of PtdIns4P synthesis against endogenous PtdIns present in the anti-caveolin co-immunoprecipitate. TLC showing that PtdIns 4-kinase co-immunoprecipitates with caveolin but not with Dynabeads alone.

The endogenous, co-immunoprecipitated PtdIns was phosphorylated by a co-immunoprecipitated PtdIns 4-kinase activity (Fig. 5C), indicating that caveolin, PtdIns, and PtdIns 4-kinase co-localize in vivo. However, the amount of PtdIns 4-kinase activity specifically co-immunoprecipitating with caveolin was consistently less than 1% of the total cellular PtdIns 4-kinase activity. These data indicate that light membrane rafts and not caveolae are the primary site of cellular PtdIns4P synthesis.

Experiments were carried out to assess the effects of the addition of PITP and EGF on PtdIns4P synthesis in anti-caveolin co-immunoprecipitates isolated on Dynabeads. Addition of EGF (100 nM) did not result in any enhancement of PtdIns 4-kinase activity in isolated caveolae, possibly because of the orientation of the receptor in the caveolar vesicles (see above). In contrast, the addition of a physiologically appropriate concentration of recombinant PITPalpha (1 nM) (42) for 5 min dramatically increased PtdIns4P production (Fig. 6), suggesting that PITPalpha stimulates PtdIns 4-kinase activity in caveolae. These results identify a common dependence of PtdIns 4-kinase activity on PITP-mediated PtdIns supply both in immunoprecipitated caveolin-rich membranes as well as non-caveolar, light membrane rafts.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   PITP stimulates endogenous PtdIns4P synthesis in immunoprecipitated caveolae. Anti-caveolin immunoprecipitates were prepared from A431 cells, and endogenous PtdIns 4-kinase activity was assayed under a variety of conditions. Phospholipids were then extracted and PtdIns4P detected by TLC. EGF (100 nm) stimulations were for 5 min. The concentration of PITP employed was (25 µg/ml).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Combining cell fractionation with immunoprecipitation revealed that PtdIns4P synthesis occurs in a CLM preparation that exhibits many of the characteristics that have previously been attributed to caveolae. In particular its low buoyant density, its enrichment in the caveolar marker protein caveolin, and the fact that it contains only a minute fraction of the total cellular protein all point toward the CLM fraction being analogous to purified caveolae. However, analysis of CLMs by electron microscopy revealed that this fraction is heterogeneous and is composed of a mixture of vesicles of different sizes. In particular the CLM preparation contained many vesicles with diameters ranging from 150 to 300 nm, which is greater than the expected ~50-90 nm size of intact caveolae (19, 30, 40, 43). It is possible that these large clear vesicles may correspond to low density raft-type regions of the plasma membrane that pinch off during sonication to form vesicular structures. This contrasts with the preparation obtained by immunodepletion of caveolin-containing vesicles from the CLM. The vesicles that are specifically immunoprecipitated from the CLM fraction by an anti-caveolin antiserum are far more homogeneous in size, indicating that the antiserum selects for 50-100-nm diameter low density vesicles. Importantly, the vesicles that were isolated on magnetic beads by the caveolin antiserum are of a size range close to the observed dimensions of caveolae from studies with whole cells. We are, however, cautious in stating that we have succeeded in isolating intact, pure caveolae as we cannot rule out the possibility that small areas of the plasma membrane that are contiguous with caveolae may pinch off during the nonspecific process of sonication to form vesicles that contain both caveolae and non-caveolar membrane (for example see Fig. 4D). Notwithstanding such provisos, our characterization of the CLM and immunoisolated caveolae indicates that density gradient ultracentrifugation of sonicated membranes does not result in pure caveolae but in a heterogeneous mixture of light membrane vesicles. Conversely, it is clear that immunoprecipitation of caveolin-containing vesicles results in a much more homogeneous preparation that exhibits many of the characteristics expected of purified caveolae (19, 30, 40, 43). These results may have implications for other studies that have implied caveolar localization of proteins solely on the basis of their co-localization with caveolin in the CLM fraction.

Our main purpose in preparing caveolae and CLMs was to investigate the hypothesis that caveolae may be important domains for the compartmentation of polyphosphoinositide metabolism and PtdIns-dependent signaling pathways. We have demonstrated that a substantial proportion of the cellular PtdIns 4-kinase activity is localized to a non-caveolar membrane fraction that resembles, at least in buoyant density, light membrane rafts, which are likely to be analogous to DIGs (40, 44, 45). The identity of this low density receptor-rich compartment is not known, but it may be analogous to similar ill-defined plasma membrane domains distinct from caveolae that have been identified in lymphocytes (45), the epithelial Caco-2 cell line (46), neuroblastomas (47), and rat lung microvasculature (30). The low buoyant density of these membrane microdomains is thought to derive from their enrichment in cholesterol and glycosylsphingolipids. There is some evidence to indicate that DIGs are contiguous with caveolae in the plasma membrane (40) and that in the presence of detergent DIGs and caveolae can fuse to form low density vesicles that render their separation purely on the basis of density gradient centrifugation difficult (40). The CLM fraction was found to contain many large vesicles, possibly derived from the plasma membrane, with diameters in the range of 100-350 nm, which were not immunoprecipitated with an anti-caveolin antiserum and may be derived from non-caveolar rafts.

Significant proportions of the cellular PtdIns 4-kinase activity, PtdIns, PtdIns4P, and PtdIns(4,5)P2 were present in the CLM fraction, but only a small fraction of the total cellular pool of PtdIns 4-kinase activity and its cognate substrate, PtdIns, were present in immunoisolated caveolae-like structures. Hence, the current study provides evidence that the localization of PtdInsP in CLM fractions results from co-localization of the enzyme responsible for its synthesis. These findings are significant, because they may indicate that receptor-activated phosphoinositide-hydrolysis previously reported in CLM (18) and phosphoinositide resupply may be coordinated within a discrete compartment of the plasma membrane. Furthermore, given the numerous reports of transmembrane receptors being present within caveolin-rich DIG preparations (21-23), the results presented here substantiate the idea that such receptors may be able to access discrete pools of phospholipids and that only a proportion of the total cellular phosphoinositide pool is immediately accessible to receptors (48). Such structural compartmentation could facilitate more efficient signaling than if the molecules were randomly distributed throughout the plasma membrane.

Studies from this group and others have led to the suggestion that PITP may be important for the continual supply of PtdIns to PtdIns 4-kinase (17, 49). A role for PITP in phosphoinositide metabolism is likely on the grounds that the endoplasmic reticulum is believed to be the primary site of PtdIns formation within the cell, necessitating that PtdIns be transported to the plasma membrane and at some stage undergo phosphorylation to form PtdInsP and PtdIns(4,5)P2. It has also been shown that in permeabilized cell preparations depleted of PITP, there is a requirement for PITP to be added back to maintain agonist-stimulated PtdIns(4,5)P2 hydrolysis (16, 50). In concordance with these ideas we found that the CLM-associated PtdIns 4-kinase activity could be enhanced by the addition of exogenous PITPalpha . It is therefore tempting to speculate that CLMs may represent a site for PITP-dependent supply of PtdIns to the plasma membrane-associated PtdIns4P synthesis machinery.

Whereas the CLM fraction is shown to contain impure caveolae, the immunoprecipitated vesicles that we isolate from CLMs fulfil certain criteria, which indicate that they are derived from plasma membrane caveolae. In particular, the immunoisolated vesicles are of low density, of a size analogous to caveolae in intact cells (40, 41, 51, 52), and can be purified using an anti-caveolin antiserum. Significantly, specifically co-immunoprecipitated PtdIns 4-kinase activity could phosphorylate endogenous PtdIns present within the anti-caveolin immunocomplex. Furthermore, this activity was stimulated by physiologically relevant concentrations of PITP, thereby indicating that PITP can supply PtdIns directly to caveolae. These observations indicate that PtdIns and PtdIns 4-kinase activity are tightly associated with caveolae in A431 cells.

An important consideration is the observation that PtdIns4P generation in our caveolae preparation accounts only for a small proportion of the total cellular PtdIns4P synthesis. These results suggest that the agonist-sensitive pool of PtdIns resides elsewhere in the cell, most likely in the low density membranes that we found to contain the bulk of the cellular PtdIns, PtdIns4P, PtdIns(4,5)P2, and EGF receptors.3 Previous studies have demonstrated that stimulation of PIC-linked receptors results in substantial turnover of polyphosphoinositides (11, 16, 49), therefore it is unlikely that the level of PtdIns4P resynthesis in caveolae-like domains would contribute significantly to such an effect. These observations argue against a major role in signal transduction for the pool of PtdIns and PtdIns 4-kinase activity associated with the caveolar fraction.

Caveolar PtdIns4P production may be required for the internalization (52-54) and exocytosis (55) roles described for caveolin-rich vesicles derived from the plasma membrane and the trans-Golgi network, respectively. In line with this view, there are precedents for a functional relationship between polyphosphoinositide synthesis and vesicular trafficking (reviewed in Ref. 56). In particular, there is evidence that PITP-dependent polyphosphoinositide production is an essential element in secretory vesicle function in neuroendocrine and myeloid cells (57-59).

In conclusion, our data indicate that caution needs to be exercised in implying caveolar compartmentation of signaling molecules solely on the basis of co-localization in caveolin-rich membranes of low buoyant density. Indeed, we demonstrate that the bulk of the cellular PtdIns pool and PtdIns4P synthesizing machinery co-fractionates with low density membranes that can be distinguished from caveolae on the basis of immunoprecipitation. Further work will be aimed at characterizing the low density membrane rafts and to analyze their contribution to the organization of PIC-dependent signaling pathways.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by an award from the Leverhulme Trust.

** To whom correspondence should be addressed. Tel.: 44-1-71-878-4033; Fax: 44-1-71-878-4040; E-mail: justin{at}ludwig.ucl.ac.uk.

1 The abbreviations used are: PIC, phosphoinositidase C; CLM, caveolin-rich light membranes; PtdIns, phosphatidylinositol; PtdIns4P, phosphatidylinositol 4-phosphate; PtdIns(4,5)P2, phosphatidylinositol 4,5-bisphosphate: PtdIns 4-kinase, phosphatidylinositol 4-kinase; PITP, phosphatidylinositol transfer protein; EGF, epidermal growth factor; TLC, thin layer chromatography; DIG(s), detergent-insoluble, glycolipid-rich domain(s); Mes, 4-morpholineethanesulfonic acid.

2 S. K. Tan and J. J. Hsuan, unpublished observations.

3 M. G. Waugh and J. J. Hsuan, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Exton, J. H. (1996) Annu. Rev. Pharmacol. Toxicol. 36, 481-509[CrossRef][Medline] [Order article via Infotrieve]
  2. Lee, S. B., and Rhee, S. G. (1995) Curr. Opin. Cell Biol. 7, 183-189[CrossRef][Medline] [Order article via Infotrieve]
  3. Fukami, K., Endo, T., Imamura, M., and Takenawa, T. (1994) J. Biol. Chem. 269, 1518-1522[Abstract/Free Full Text]
  4. Miki, H., Miura, K., and Takenawa, T. (1996) EMBO J. 15, 5326-5335[Abstract]
  5. Shibasaki, Y., Ishihara, H., Kizuki, N., Asano, T., Oka, Y., and Yazaki, Y. (1997) J. Biol. Chem. 272, 7578-7581[Abstract/Free Full Text]
  6. Lemmon, M. A., Falasca, M., Ferguson, K. M., and Schlessinger, J. (1997) Trends Cell Biol. 7, 237-242[CrossRef]
  7. Toker, A., and Cantley, L. C. (1997) Nature 387, 673-676[CrossRef][Medline] [Order article via Infotrieve]
  8. Salim, K., Bottomley, M. J., Querfurth, E., Zvelebil, M. J., Gout, I., Scaife, R., Margolis, R. L., Gigg, R., Smith, C. I., Driscoll, P. C., Waterfield, M. D., and Panayotou, G. (1997) EMBO J. 15, 6241-6250[Abstract]
  9. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261-269[Medline] [Order article via Infotrieve]
  10. Datta, K., Bellacosa, A., Chan, T. O., and Tsichlis, P. N. (1996) J. Biol. Chem. 271, 30835-30839[Abstract/Free Full Text]
  11. Pike, L. J., and Eakes, A. T. (1987) J. Biol. Chem. 262, 1644-1651[Abstract/Free Full Text]
  12. Walker, D. H., and Pike, L. J. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7513-7517[Abstract]
  13. Thompson, D. M., Cochet, C., Chambaz, E. M., and Gill, G. N. (1985) J. Biol. Chem. 260, 8824-8830[Abstract/Free Full Text]
  14. Kauffmann-Zeh, A., Klinger, R., Endemann, G., Waterfield, M. D., Wetzker, R., and Hsuan, J. J. (1994) J. Biol. Chem. 269, 31243-31251[Abstract/Free Full Text]
  15. Cochet, C., Filhol, O., Payrastre, B., Hunter, T., and Gill, G. N. (1991) J. Biol. Chem. 266, 637-644[Abstract/Free Full Text]
  16. Thomas, G. M., Cunningham, E., Fensome, A., Ball, A., Totty, N. F., Truong, O., Hsuan, J. J., and Cockcroft, S. (1993) Cell 74, 919-928[Medline] [Order article via Infotrieve]
  17. Kauffmann-Zeh, A., Thomas, G. M., Ball, A., Prosser, S., Cunningham, E., Cockcroft, S., and Hsuan, J. J. (1995) Science 268, 1188-1190[Medline] [Order article via Infotrieve]
  18. Pike, L. J., and Casey, L. (1996) J. Biol. Chem. 271, 26453-26456[Abstract/Free Full Text]
  19. Parton, R. G. (1996) Curr. Opin. Cell Biol. 8, 542-548[CrossRef][Medline] [Order article via Infotrieve]
  20. Brown, D., and Waneck, G. L. (1992) J. Am. Soc. Nephrol. 3, 895-906[Abstract]
  21. Liu, J., Oh, P., Horner, T., Rogers, R. A., and Schnitzer, J. E. (1997) J. Biol. Chem. 272, 7211-7222[Abstract/Free Full Text]
  22. Chun, M., Liyanage, U. K., Lisanti, M. P., and Lodish, H. F. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11728-11732[Abstract/Free Full Text]
  23. Smart, E. J., Ying, Y. S., Mineo, C., and Anderson, R. G. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10104-10108[Abstract]
  24. Sargiacomo, M., Sudol, M., Tang, Z., and Lisanti, M. P. (1993) J. Cell Biol. 122, 789-807[Abstract]
  25. Chang, W. J., Ying, Y. S., Rothberg, K. G., Hooper, N. M., Turner, A. J., Gambliel, H. A., De Gunzburg, J., Mumby, S. M., Gilman, A. G., and Anderson, R. G. (1994) J. Cell Biol. 126, 127-138[Abstract]
  26. Li, S., Okamoto, T., Chun, M., Sargiacomo, M., Casanova, J. E., Hansen, S. H., Nishimoto, I., and Lisanti, M. P. (1995) J. Biol. Chem. 270, 15693-15701[Abstract/Free Full Text]
  27. Li, S., Couet, J., and Lisanti, M. P. (1996) J. Biol. Chem. 271, 29182-29190[Abstract/Free Full Text]
  28. Hope, H. R., and Pike, L. J. (1996) Mol. Biol. Cell 7, 843-851[Abstract]
  29. Huang, C., Hepler, J. R., Chen, L. T., Gilman, A. G., Anderson, R. G. W., and Mumby, S. M. (1997) Mol. Biol. Cell 8, 2365-2378[Abstract/Free Full Text]
  30. Stan, R. V., Roberts, W. G., Predescu, D., Ihida, K., Saucan, L., Ghitescu, L., and Palade, G. E. (1997) Mol. Biol. Cell 8, 595-605[Abstract]
  31. Monaco, M. E., and Gershengorn, M. C. (1992) Endocr. Rev. 13, 707-718[Medline] [Order article via Infotrieve]
  32. Song, S. K., Li, S., Okamoto, T., Quilliam, L. A., Sargiacomo, M., and Lisanti, M. P. (1996) J. Biol. Chem. 271, 9690-9697[Abstract/Free Full Text]
  33. Williams, C. H., and Kamin, H. (1962) J. Biol. Chem. 237, 587-594[Free Full Text]
  34. Lawson, D. (1983) J. Cell Biol. 97, 1891-1905[Abstract]
  35. Bickel, P. E., Scherer, P. E., Schnitzer, J. E., Oh, P., Lisanti, M. P., and Lodish, H. F. (1997) J. Biol. Chem. 272, 13793-13802[Abstract/Free Full Text]
  36. Shaul, P. W., Smart, E. J., Robinson, L. G., German, Z., Yuhanna, I. S., Ying, Y., Anderson, R. G., and Michel, T. (1996) J. Biol. Chem. 271, 6518-6522[Abstract/Free Full Text]
  37. Bilderback, T. R., Grigsby, R. J., and Dobrowsky, R. T. (1997) J. Biol. Chem. 272, 10922-10927[Abstract/Free Full Text]
  38. Endemann, G., Dunn, S. N., and Cantley, L. C. (1987) Biochemistry 26, 6845-6852[Medline] [Order article via Infotrieve]
  39. Pike, M. C., and Arndt, C. (1988) J. Immunol. 140, 1967-1973[Abstract/Free Full Text]
  40. Schnitzer, J. E., McIntosh, D. P., Dvorak, A. M., Liu, J., and Oh, P. (1995) Science 269, 1435-1439[Medline] [Order article via Infotrieve]
  41. Bruns, R. R., and Palade, G. E. (1968) J. Cell Biol. 37, 244-276[Abstract/Free Full Text]
  42. Kular, G., Loubtchenkov, M., Swigart, P., Whatmore, J., Ball, A., Cockcroft, S., and Wetzker, R. (1997) Biochem. J. 325, 299-301[Medline] [Order article via Infotrieve]
  43. Parton, R. G., and Simons, K. (1995) Science 269, 1398-1399[Medline] [Order article via Infotrieve]
  44. Brown, D. A., and Rose, J. K. (1992) Cell 68, 533-544[Medline] [Order article via Infotrieve]
  45. Fra, A. M., Williamson, E., Simons, K., and Parton, R. G. (1994) J. Biol. Chem. 269, 30745-30748[Abstract/Free Full Text]
  46. Mirre, C., Monlauzeur, L., Garcia, M., Delgrossi, M. H., and Le Bivic, A. (1996) Am. J. Physiol. 271, C887-C894[Abstract/Free Full Text]
  47. Gorodinsky, A., and Harris, D. A. (1995) J. Cell Biol. 129, 619-627[Abstract]
  48. Imai, A., and Gershengorn, M. C. (1987) Nature 325, 726-728[Medline] [Order article via Infotrieve]
  49. Cunningham, E., Thomas, G. M., Ball, A., Hiles, I., and Cockcroft, S. (1995) Curr. Biol. 5, 775-783[Medline] [Order article via Infotrieve]
  50. Batty, I. H., Currie, R. A., and Downes, C. P. (1998) Biochem. J. 330, 1069-1077[Medline] [Order article via Infotrieve]
  51. Parton, R. G. (1994) J. Histochem. Cytochem. 42, 155-166[Abstract/Free Full Text]
  52. Parton, R. G., Joggerst, B., and Simons, K. (1994) J. Cell Biol. 127, 1199-1215[Abstract]
  53. Schnitzer, J. E., Liu, J., and Oh, P. (1995) J. Biol. Chem. 270, 14399-14404[Abstract/Free Full Text]
  54. Schnitzer, J. E., Oh, P., and McIntosh, D. P. (1996) Science 274, 239-242[Abstract/Free Full Text]
  55. Scheiffele, P., Verkade, P., Fra, A. M., Virta, H., Simons, K., and Ikonen, E. (1998) J. Cell Biol. 140, 795-806[Abstract/Free Full Text]
  56. Wirtz, K. W. A. (1997) Biochem. J. 324, 353-360[Medline] [Order article via Infotrieve]
  57. Hay, J. C., Fisette, P. L., Jenkins, G. H., Fukami, K., Takenawa, T., Anderson, R. A., and Martin, T. F. (1995) Nature 374, 173-177[CrossRef][Medline] [Order article via Infotrieve]
  58. Wiedemann, C., Schafer, T., and Burger, M. M. (1996) EMBO J. 15, 2094-2101[Abstract]
  59. Fensome, A., Cunningham, E., Prosser, S., Tan, S. K., Swigart, P., Thomas, G., Hsuan, J., and Cockcroft, S. (1996) Curr. Biol. 6, 730-738[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.